Amifostine


Generic Medicine Info
Contraindications
Hypotension, dehydration. Lactation.
Special Precautions
Patient w/ CV or cerebrovascular disease (e.g. ischaemic heart disease, arrhythmias, CHF, history of stroke or transient ischaemic attack). Renal impairment. Pregnancy. Monitoring Parameters Monitor BP every 5 min during infusion (prior to chemotherapy) or at least before and immediately after infusion (prior to radiotherapy); and thereafter as clinically indicated. Monitor serum Ca levels in patients at risk of hypocalcaemia. Evaluate for cutaneous reactions prior to each dose.
Adverse Reactions
Reduction in BP; nausea, vomiting; flushing, chills, malaise, fever, dizziness, somnolence, hiccups, sneezing, cough; rash, pruritus, urticaria, chest tightness, laryngeal oedema; severe acute allergic reaction; pain, inflammation, bruising, phlebitis, and local swelling at inj site. Rarely, loss of consciousness, tachycardia, bradycardia, arrhythmias (e.g. atrial fibrillation/flutter, supraventricular tachycardia), chest pain, myocardial ischaemia, MI, cardiac and resp arrest, convulsions, dyspnoea, apnoea, hypoxia, renal failure, hypocalcaemia, transient HTN.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous toxicity.
Drug Interactions
May potentiate hypotension w/ antihypertensive medications.
ATC Classification
V03AF05 - amifostine ; Belongs to the class of detoxifying agents used in antineoplastic treatment.
Disclaimer: This information is independently developed by CIMS based on amifostine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in